Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy.
Joyce O'Shaughnessy
Consultant or Advisory Role - Johnson & Johnson
Margaret K. Yu
Employment or Leadership Position - Janssen Research Development
Jill Kearney
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Julie S. Larsen
Employment or Leadership Position - Janssen research and development
Stock Ownership - Janssen Pharmaceutical
Arturo Molina
Employment or Leadership Position - Janssen research and development
Stock Ownership - Johnson & Johnson
Stephen R. D. Johnston
No relevant relationships to disclose